[
  {
    "question": "Typical scenario of left hemifacial spasm whats the tx",
    "option_a": "Botulinum toxin",
    "option_b": ") or surgical interventions (option C) are considered only when botulinum toxin fails or is contraindicated, and physical therapy or oral muscle relaxants (option D) do not have robust evidence for primary therapy.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Hemifacial spasm is a movement disorder characterized by involuntary contractions of the muscles on one side of the face. The condition is frequently due to vascular compression of the facial nerve at the root exit zone. Established first-line management includes local treatment to ameliorate the symptoms. The disorder is thought to result from ephaptic transmission due to demyelination of the facial nerve fibers, usually secondary to a loop of an artery compressing the nerve. This vascular compression induces hyperactivity and abnormal muscle contractions. Botulinum toxin, by blocking acetylcholine release at the neuromuscular junction, directly counteracts this hyperactivity. Patients typically present with unilateral, intermittent, or persistent contractions that can lead to functional impairment and social embarrassment. Botulinum toxin injections are highly effective in reducing these spasms and have become the first-line treatment due to their safety profile and efficacy. Diagnosis is primarily clinical, with imaging (MRI/MRA) sometimes used to exclude other causes or assess for vascular compression if considering surgery. Differential diagnoses include blepharospasm and focal seizures, which can be differentiated based on clinical history and examination findings. First-line treatment is botulinum toxin injections, which provide symptomatic relief by reducing the frequency and intensity of facial muscle contractions. In refractory cases, surgical options like microvascular decompression may be considered. For pregnant and lactating patients, the safety profile of botulinum toxin remains under study; however, it is generally recommended to avoid elective procedures unless the benefits significantly outweigh the risks. Option A: Botulinum toxin \u2013 Correct, as it is the established first-line treatment for hemifacial spasm. Alternative treatments such as anticonvulsants (option B) or surgical interventions (option C) are considered only when botulinum toxin fails or is contraindicated, and physical therapy or oral muscle relaxants (option D) do not have robust evidence for primary therapy. 1. Botulinum toxin injections provide localized, effective, and reversible treatment for hemifacial spasm. 2. Always consider imaging to rule out secondary causes in atypical presentations. 3. Microvascular decompression is a surgical option for refractory cases but carries higher risks. Numerous randomized controlled trials and meta-analyses support botulinum toxin as the first-line treatment for hemifacial spasm, showing significant improvement in symptoms with a favorable safety profile.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "They brought scenario from description it suggest dyt11 asking what is the type of myoclonus, her father has similar condition that improves with alcohol",
    "option_a": "Essential myoclonus",
    "option_b": "Cortical myoclonus is incorrect because cortical hyperexcitability would be evident on EEG and usually does not improve with alcohol, which is inconsistent with the clinical scenario described.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "DYT11 myoclonus-dystonia is a genetically inherited movement disorder characterized by myoclonus and dystonia. The condition is often familial and is notable for its unique response to alcohol, which typically improves the myoclonic symptoms. The disorder is usually associated with mutations in the SGCE gene and is inherited in an autosomal dominant pattern with maternal imprinting. The myoclonus in DYT11 is generally subcortical in origin (often described as essential myoclonus) rather than cortical. The improvement with alcohol is thought to be due to enhancement of GABAergic transmission, reducing abnormal neuronal firing. Clinically, patients present with myoclonic jerks along with mild dystonic features. A positive family history and the characteristic improvement of myoclonus with alcohol consumption (as reported in the patient's father) are strong supportive features for DYT11 myoclonus-dystonia. The diagnosis is largely clinical, with genetic testing providing confirmatory evidence. Differential diagnoses include other disorders with myoclonus such as cortical myoclonus (which is typically associated with EEG abnormalities and is often stimulus-sensitive), and secondary causes like metabolic encephalopathies. Detailed family history and the alcohol responsiveness are key distinguishing features. Treatment primarily targets symptom control. First-line therapy includes benzodiazepines and other agents such as levetiracetam. In refractory cases, deep brain stimulation (DBS) targeting the globus pallidus or thalamus may be considered. For pregnant or lactating patients, the use of benzodiazepines requires careful consideration due to potential fetal effects; dose adjustment or alternative therapies with a better safety profile may be needed per current obstetric guidelines. Option A: Essential myoclonus \u2013 Correct, as the myoclonus in DYT11 myoclonus-dystonia is typically subcortical (essential) in nature. Option B: Cortical myoclonus is incorrect because cortical hyperexcitability would be evident on EEG and usually does not improve with alcohol, which is inconsistent with the clinical scenario described. 1. DYT11 myoclonus-dystonia is characterized by its autosomal dominant inheritance and striking improvement of symptoms with alcohol. 2. Myoclonus in this condition is typically subcortical (essential myoclonus). 3. A detailed family history is crucial in guiding diagnosis. Recent studies emphasize the genetic underpinnings of DYT11 and support the role of symptomatic treatment while highlighting promising outcomes with advanced therapies like DBS for refractory cases. Alcohol responsiveness remains a distinguishing clinical feature despite not being a recommended treatment modality due to potential for abuse.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Orthostatic tremor what is next investigation",
    "option_a": "NCS/EMG",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor (OT) is a rare movement disorder characterized by a high-frequency tremor in the legs that is present when standing and resolves when sitting or walking. The diagnosis is confirmed by demonstrating the tremor with neurophysiological testing. OT is believed to result from abnormal oscillatory activity in the central nervous system, though its exact mechanism remains uncertain. The characteristic high-frequency (typically 13\u201318 Hz) burst pattern during standing is best captured with surface electromyography (EMG). This distinctive electrophysiologic fingerprint distinguishes it from other tremor disorders. Patients with OT experience a sense of unsteadiness or shaking in the legs when standing, which can significantly impair their daily activities. The rapid tremor bursts seen on EMG correspond to these symptoms. In many cases, the tremors are too subtle to appreciate on physical exam alone, making instrumental testing essential. The diagnosis of OT is based on clinical suspicion followed by neurophysiological confirmation using surface EMG. Differential diagnoses include essential tremor, anxiety-related tremor, and other forms of postural tremor; these can be differentiated by tremor frequency, pattern, and response to position. MRI may be utilized to rule out structural lesions but is not diagnostic of OT. First-line management of OT may include medications such as clonazepam and gabapentin that can reduce tremor severity. However, before initiating treatment, the appropriate diagnostic investigation is surface EMG (often combined with NCS) to confirm the diagnosis. In pregnant or lactating patients, the choice of therapy would require careful risk-benefit analysis, with clonazepam generally avoided unless absolutely necessary due to fetal risk; alternative agents with better safety profiles during pregnancy might be considered. Option A: NCS/EMG \u2013 Correct. Neurophysiological studies, particularly surface EMG, are essential to demonstrate the high-frequency tremor burst pattern seen in OT. Other modalities like MRI are more useful in excluding alternative etiologies rather than confirming OT. 1. Orthostatic tremor is best confirmed by surface EMG showing high-frequency bursts during standing. 2. Symptoms typically resolve when the patient is seated or walking. 3. Differential diagnosis includes other tremor disorders, but the distinctive EMG pattern is diagnostic. Recent guidelines and studies reinforce the role of neurophysiological testing in OT diagnosis. While various pharmacotherapies are under investigation, EMG remains the cornerstone for diagnosis, and ongoing research is focused on optimizing medical management, including safety considerations in special populations.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "MSA scenario asking about radiological findings",
    "option_a": "(Hot cross bun sign) correctly identifies the radiological hallmark of MSA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Multiple System Atrophy (MSA) is a neurodegenerative disorder presenting with parkinsonian and/or cerebellar features as well as autonomic dysfunction. Radiological clues are key to differentiating its variants. The 'hot cross bun' sign is a classic imaging finding on T2\u2010weighted MRI that highlights the degeneration of pontocerebellar fibers, especially in the MSA-cerebellar (MSA-C) subtype. The hot cross bun sign results from selective degeneration of pontine neurons and the transverse pontocerebellar fibers, which leads to a cruciform hyperintensity in the pons on T2-weighted MRI. This degeneration is part of a broader spectrum of neurodegenerative changes that include olivopontocerebellar atrophy seen in MSA-C. Patients with MSA often present with a mix of parkinsonian features (bradykinesia, rigidity) and cerebellar signs (ataxia, dysmetria) along with autonomic dysfunction. The presence of a hot cross bun sign in the appropriate clinical setting supports the diagnosis of MSA-C as opposed to other atypical parkinsonian syndromes. Differential diagnoses include Parkinson\u2019s disease (which usually lacks cerebellar involvement and the hot cross bun sign), Progressive Supranuclear Palsy (PSP) characterized by the hummingbird sign, and MSA-parkinsonian subtype (MSA-P) where a putaminal rim sign might be seen. Clinical history, examination, and MRI findings are all integrated to reach a final diagnosis. Management of MSA is largely symptomatic and multidisciplinary. First-line approaches focus on managing parkinsonism (levodopa as a trial, though response is modest), addressing autonomic symptoms (using midodrine or fludrocortisone for orthostatic hypotension), and providing supportive therapies (physical and occupational therapy). In pregnancy, medication risks must be weighed carefully, but because MSA typically manifests in later adulthood, pregnancy is rarely a clinical concern. Lactation considerations are similar, with close monitoring and risk\u2013benefit assessments. Option a (Hot cross bun sign) correctly identifies the radiological hallmark of MSA-C. Other options like the putaminal rim sign are more associated with the parkinsonian variant (MSA-P) and are less specific; diffuse cortical atrophy is non-specific; the hummingbird sign is seen in PSP; and hyperintense substantia nigra is not characteristic of MSA. 1. The hot cross bun sign is a cruciform T2 hyperintensity in the pons and is highly suggestive of MSA-C. 2. Always correlate radiological findings with clinical presentation in neurodegenerative disorders. 3. Differentiating between MSA-P and MSA-C is essential for guiding management and prognostication. Recent neuroimaging studies continue to validate the hot cross bun sign as a supportive feature for MSA-C. While not present in all cases, its specificity in the correct clinical setting aids in early diagnosis. Updated consensus guidelines emphasize MRI findings alongside clinical criteria to bolster diagnostic accuracy.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Orthostatic tremor didn\u2019t response to clonazepam what\u2019s next",
    "option_a": "",
    "option_b": "reflects that gabapentin, the recommended second",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Orthostatic tremor (OT) is a rare movement disorder characterized by rapid, rhythmic tremor in the legs that occurs on standing and is relieved by sitting or walking. Management typically begins with clonazepam, a benzodiazepine with GABAergic properties. The exact mechanism of OT remains unclear, though abnormal oscillatory activity within central motor circuits is implicated. It is not primarily related to dopaminergic deficits, which is why dopaminergic medications like L-Dopa fail to provide significant relief. Patients with OT experience a distinct sensation of unsteadiness or trembling exclusively when standing, with immediate improvement upon sitting. This unique presentation helps differentiate OT from other tremor disorders. Clinically, OT is differentiated from essential tremor (which is more static and bilateral during action) and from other causes of postural instability. Electrophysiological studies such as surface electromyography (EMG) can confirm the high-frequency tremor pattern seen in OT. First-line treatment for OT is clonazepam. When patients do not respond or tolerate clonazepam, gabapentin is recognized as a second-line agent. In pregnancy and lactation, both clonazepam and gabapentin carry risks; clonazepam is generally classified as Category D and gabapentin as Category C in pregnancy. Management in pregnant women requires a careful benefit-risk assessment, with possible dose adjustments and close monitoring. Option a (L-Dopa) is incorrect because OT does not have a significant dopaminergic deficit, and L-Dopa has not shown benefit in OT. Option b reflects that gabapentin, the recommended second-line treatment, is not among the provided options, making it the correct choice by process of elimination and understanding of the therapeutic hierarchy. 1. Orthostatic tremor is distinct in that it occurs on standing and improves with sitting or walking. 2. Clonazepam is the first-line treatment, with gabapentin as a recognized alternative. 3. Dopaminergic agents like L-Dopa are ineffective in OT. Updated clinical reviews and guidelines consistently support the use of clonazepam as first-line therapy and identify gabapentin as an effective second-line agent in the treatment of OT. Recent case series have reinforced the limited efficacy of dopaminergic interventions in this condition.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "32 female with hx of parkinson disease came with parkinson symptoms, she is tailer with disabling symptoms including rest tremor, she had remarkable improvement with L-dopa (I believe they mean her cousin or so) what to do",
    "option_a": "(Dopamine agonist) is less effective in controlling disabling symptoms such as resting tremor and may lead to side effects including impulse control disorders. Option b (Levodopa) is optimal because it has been shown to produce marked improvement in motor symptoms, making it the best choice.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) is characterized by dopaminergic neuronal loss in the substantia nigra, leading to motor symptoms such as bradykinesia, rigidity, and tremor. Levodopa remains the most efficacious medication for symptom relief. PD pathophysiology involves the depletion of dopamine due to progressive neurodegeneration. Levodopa is converted to dopamine in the brain, replenishing the deficient neurotransmitter and ameliorating motor symptoms. In younger PD patients, a dilemma often exists between delaying levodopa-induced motor complications with dopamine agonists and achieving optimal symptom control. When disabling symptoms such as a marked resting tremor are present, and the patient demonstrates a robust response to levodopa, its use is preferred. Diagnosis is made clinically, supported by a positive response to levodopa. Differential diagnoses include atypical parkinsonian syndromes and drug-induced parkinsonism, but a notable improvement with levodopa is strongly indicative of classic PD. For patients with disabling motor symptoms, levodopa combined with carbidopa is considered first-line therapy due to its superior symptomatic relief. In younger patients with milder symptoms, dopamine agonists might be considered to delay levodopa-related complications. In pregnancy, levodopa is relatively safe compared to other options and is the treatment of choice if motor symptoms are disabling, though it should be used at the lowest effective dose with close monitoring. Option a (Dopamine agonist) is less effective in controlling disabling symptoms such as resting tremor and may lead to side effects including impulse control disorders. Option b (Levodopa) is optimal because it has been shown to produce marked improvement in motor symptoms, making it the best choice. 1. Levodopa is considered the gold standard treatment for motor symptoms in PD. 2. In cases of disabling symptoms, its superior efficacy outweighs the potential risk of motor complications. 3. When a patient shows a robust response to levodopa, it confirms the diagnosis of typical PD. Recent guidelines continue to endorse levodopa as the cornerstone of symptomatic management in PD. Emerging research also supports the safety profile of levodopa in younger patients when used judiciously, with a particular emphasis on individualized treatment strategies in special populations, including women of childbearing age.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What would response to dopamine agonist not L-dopa",
    "option_a": "(Aromatic decarboxylase",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "The treatment response in parkinsonian disorders often hinges on the conversion of levodopa to dopamine. Key enzymatic steps are essential for effective treatment, and failure of response to levodopa necessitates an evaluation of these pathways. Levodopa is dependent on the enzyme aromatic decarboxylase (AADC) for its conversion to dopamine in the brain. A deficiency or inhibition of AADC results in insufficient dopamine production from levodopa. Conversely, dopamine agonists directly stimulate dopamine receptors, bypassing the need for conversion by AADC. Patients who respond to dopamine agonists but not to levodopa may have an underlying issue with AADC, leading to inadequate conversion of levodopa to dopamine. This metabolic bottleneck is key in explaining the differential response. In patients with an atypical response pattern to levodopa, enzyme assays or genetic studies may be considered to evaluate for AADC deficiency. Differential diagnoses include other metabolic or genetic disorders affecting dopamine synthesis, but clinical context and response to treatment are central. Management of AADC deficiency involves the use of dopamine agonists to bypass the deficient enzymatic step. Supportive care and multidisciplinary management are essential. While data in pregnancy and lactation on AADC deficiency are limited given its rarity, treatment decisions should be guided by expert consultation and a careful benefit-risk analysis, with a preference for agents with established safety profiles in these populations if needed. Option a (Aromatic decarboxylase - AADC) correctly identifies the enzyme whose deficiency would explain a poor response to levodopa yet a preserved response to dopamine agonists. Other options (which might include enzymes involved in dopamine metabolism like MAO or COMT) do not directly affect the conversion of levodopa to dopamine. 1. AADC is critical for converting levodopa to dopamine; its deficiency impairs levodopa\u2019s efficacy. 2. Dopamine agonists can be effective in bypassing this enzymatic block. 3. Recognizing a differential response to therapy can prompt evaluation for rare metabolic disorders. Recent case reports and studies have shed light on the importance of AADC activity in levodopa responsiveness. Current research supports the use of dopamine agonists in patients with suspected AADC deficiency, reinforcing the concept that bypassing the enzymatic step can be beneficial when standard levodopa therapy fails.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "L-dopa in PSP treat what",
    "option_a": "(Bradykinesia) and Option B (Rigidity) are both partially responsive to L",
    "option_b": "",
    "option_c": "(Gait instability) largely results from non",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A, B",
    "subspecialty": "Movement Disorders",
    "explanation": "L-dopa is a dopamine precursor used to restore deficient dopaminergic signaling in movement disorders. In Progressive Supranuclear Palsy (PSP), certain features such as bradykinesia and rigidity are partly related to nigrostriatal dopamine loss, even though PSP is primarily a tauopathy with additional non-dopaminergic involvement. PSP is characterized by the accumulation of abnormal tau protein, leading to neurodegeneration in the basal ganglia, brainstem, and cerebellum. While the degeneration is widespread, the dopaminergic nigrostriatal pathway is one of the affected systems. L-dopa helps by partially replenishing dopamine, which can improve symptoms directly linked to dopaminergic insufficiency such as bradykinesia and rigidity. However, gait instability is more related to brainstem and cerebellar dysfunction, limiting L-dopa\u2019s efficacy in that domain. Clinically, patients with PSP often present with parkinsonian features including bradykinesia and rigidity. Although some improvement with L-dopa may be observed in these motor symptoms, patients typically continue to suffer from postural instability and gait disturbances which do not respond well to dopaminergic therapy. The diagnostic workup of PSP involves clinical evaluation\u2014recognizing early falls, vertical gaze palsy, and poor L-dopa response overall\u2014supported by neuroimaging (MRI) to rule out other pathologies. Differential diagnoses include Parkinson\u2019s disease (which shows a robust response to L-dopa), multiple system atrophy, and corticobasal syndrome. According to current guidelines, a trial of L-dopa can be considered in PSP to improve dopaminergic symptom components such as bradykinesia and rigidity, even though the response tends to be modest. First-line management is symptomatic, including physical and occupational therapy. In pregnant or lactating patients, the use of L-dopa requires careful benefit-risk evaluation; while levodopa has been used in Parkinson\u2019s disease during pregnancy, its role in PSP is less established and should be individualized. Option A (Bradykinesia) and Option B (Rigidity) are both partially responsive to L-dopa due to their dopaminergic basis. Option C (Gait instability) largely results from non-dopaminergic pathology (brainstem and cerebellar involvement) and does not improve with L-dopa. The marked answer only included A, which is incomplete; therefore, the correct answer should be both A and B. 1. PSP is poorly responsive to L-dopa compared to Parkinson\u2019s disease. 2. Improvement with L-dopa in PSP is usually limited to bradykinesia and rigidity, not axial or gait disturbances. Recent studies continue to show that while some PSP patients may experience modest symptomatic relief with L-dopa for dopaminergic deficits, the overall prognosis remains poor. Ongoing research is exploring disease-modifying therapies, with current management emphasizing supportive care.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Female with hx of action and intention tremor, dropping things, slightly asymmetric family hx what is the dx",
    "option_a": "(Physiological tremor) is incorrect because it is a normal variant with low amplitude and limited functional impact. Option B (Essential tremor) correctly describes the clinical scenario with action and intention tremors, a family history, and functional impairment.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential Tremor (ET) is a common movement disorder characterized by action and postural tremors. It typically affects the upper extremities and may lead to functional impairment, as seen with difficulties in tasks such as holding objects. The exact etiology of ET is not completely understood, but it is thought to involve abnormal oscillatory activity in the cerebellar-thalamic-cortical circuits. A genetic predisposition is noted in many patients, and the condition frequently exhibits an autosomal dominant pattern with variable penetrance, which may account for any asymmetry in family histories. Patients with ET present with a tremor that is most evident during action (such as writing or eating) and may be accompanied by an intention component. The history of dropping things reflects the significant functional impairment that can occur even with a slightly asymmetric family history. The diagnosis of ET is clinical and is based on the presence of action or postural tremors with a possible family history. Differential diagnoses include enhanced physiologic tremor (which is usually benign and symmetric) and tremors secondary to hyperthyroidism, medication, or other neurological disorders such as cerebellar tremor. Examination, patient history, and sometimes thyroid function tests help differentiate these conditions. First-line treatments include beta-blockers (e.g., propranolol) and primidone. Second-line options may include gabapentin or topiramate if there is an inadequate response. In pregnant patients, the use of propranolol must be carefully considered due to potential fetal growth restriction, and primidone is generally avoided due to teratogenic risk; in lactating women, drug choice requires balancing the benefits with potential effects on the infant. Option A (Physiological tremor) is incorrect because it is a normal variant with low amplitude and limited functional impact. Option B (Essential tremor) correctly describes the clinical scenario with action and intention tremors, a family history, and functional impairment. 1. ET is typically an action or postural tremor with a familial tendency. 2. The presence of an intention tremor does not rule out ET. Recent clinical guidelines continue to support beta-blockers and primidone as first-line therapy for ET. Research into deep brain stimulation and focused ultrasound has provided alternative therapeutic approaches for refractory cases.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Dyt11 what is the tx, he brought scenario suggestive improve with alcohol",
    "option_a": "(Clonazepam) is correct because it directly enhances GABA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "DYT11, or myoclonus-dystonia, is a genetic movement disorder characterized by the presence of myoclonus (sudden brief muscle jerks) and dystonia. A characteristic feature is the improvement of symptoms with alcohol, which suggests a role for GABAergic modulation in its pathogenesis. The disorder is usually associated with mutations in the SGCE gene. This mutation leads to dysfunction in the basal ganglia circuits and abnormal GABAergic inhibition. The clinical improvement seen with alcohol is attributed to the enhancement of GABA-A receptor-mediated inhibition, a mechanism that can be mimicked pharmacologically by benzodiazepines like clonazepam. Patients with DYT11 often report symptomatic improvement after alcohol intake, which supports the use of clonazepam. This medication reduces both myoclonic jerks and dystonic movements by potentiating inhibitory neurotransmission. Diagnosis is primarily based on clinical features and family history, distinguishing myoclonus-dystonia from other movement disorders such as other forms of dystonia, myoclonic epilepsy, or essential tremor. Genetic testing for SGCE mutations can be confirmatory. First-line treatment, as recommended by current guidelines, includes benzodiazepines\u2014especially clonazepam\u2014for symptomatic relief. Second-line medications may include levetiracetam or other agents with GABAergic activity. In pregnancy, the use of clonazepam must be approached with caution due to potential teratogenic effects and neonatal withdrawal; alternative non-pharmacologic strategies or close monitoring may be warranted, and similar precautions apply during lactation. Option A (Clonazepam) is correct because it directly enhances GABA-A receptor-mediated inhibition, mirroring the beneficial effects of alcohol in DYT11. Other options, such as levodopa or anticholinergics, do not address the underlying GABAergic dysfunction and are less effective. 1. Myoclonus-dystonia frequently improves with alcohol due to enhanced GABAergic transmission. 2. Clonazepam is widely recognized as the first-line treatment for DYT11. The latest research reinforces clonazepam as a first-line agent for DYT11, with emerging studies evaluating the role of deep brain stimulation for refractory cases. Consensus guidelines continue to advocate for a tailored approach based on patient-specific factors including pregnancy and lactation status.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario of Essential palatal myoclonus what to do",
    "option_a": "(MRI brain) is correct as it is the essential diagnostic step to exclude structural lesions in the Guillain",
    "option_b": "(EEG) is incorrect since the condition is not epileptic in nature, and Option C (ignoring treatment) is inappropriate because even though treatment might be conservative, proper evaluation is necessary.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential palatal myoclonus is an involuntary, rhythmic movement of the palatal muscles that is not secondary to a visible structural lesion. It is important to differentiate the essential form from symptomatic palatal myoclonus, which is associated with identifiable lesions in the brainstem or cerebellum. The symptomatic form of palatal myoclonus typically stems from lesions affecting the Guillain-Mollaret triangle (a circuit involving the red nucleus, inferior olivary nucleus, and dentate nucleus). In contrast, essential palatal myoclonus does not have an identifiable structural lesion on neuroimaging and may have a more functional or idiopathic basis. Patients presenting with palatal myoclonus may experience audible clicking sounds and visible rhythmic contractions of the soft palate. A key step in the evaluation is to verify that there is no underlying brain lesion that might require different management. The initial diagnostic step is obtaining a brain MRI to exclude structural lesions, particularly in the brainstem and cerebellum. Differential diagnoses include secondary (symptomatic) palatal myoclonus caused by lesions in the Guillain-Mollaret triangle, epileptic palatal myoclonus, or medication-induced causes. An EEG is not typically useful in this context. The first step in management is to perform an MRI of the brain to rule out any structural pathology. If the MRI is normal, management options for symptomatic relief may include oral medications (e.g., benzodiazepines) or botulinum toxin injections for severe cases. In pregnant or lactating women, the use of neuroimaging should follow safety protocols (avoiding unnecessary contrast) and medication choices should be individualized to minimize fetal or neonatal risk. Option A (MRI brain) is correct as it is the essential diagnostic step to exclude structural lesions in the Guillain-Mollaret triangle. Option B (EEG) is incorrect since the condition is not epileptic in nature, and Option C (ignoring treatment) is inappropriate because even though treatment might be conservative, proper evaluation is necessary. 1. MRI is the diagnostic modality of choice to differentiate essential from symptomatic palatal myoclonus. 2. Essential palatal myoclonus is a diagnosis of exclusion after ruling out structural lesions. Current guidelines emphasize the importance of neuroimaging in the evaluation of palatal myoclonus. Recent studies also explore the role of targeted therapies such as botulinum toxin for symptomatic management when conservative measures are inadequate.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Clear scenario of vascular PD what to do",
    "option_a": "(control hypertension) is correct. It emphasizes addressing the vascular pathology by managing modifiable risk factors. Other options (not fully presented) that might have focused on initiating dopaminergic therapy or neglecting risk factor control would be inappropriate, since VP is best managed by preventing further cerebrovascular injury.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Vascular parkinsonism (VP) is a form of secondary parkinsonism in which typical parkinsonian signs (rigidity, bradykinesia, gait disturbance) arise due to cerebrovascular disease rather than degeneration of the substantia nigra. In VP, clinical features often include a predominance of lower body involvement, gait instability, and infrequent tremor. VP results from multiple small infarcts or chronic ischemic changes affecting the basal ganglia, subcortical white matter, or other strategic regions. Damage to these areas disrupts normal motor circuits. The underlying vascular risk factors such as hypertension, diabetes, and atherosclerosis lead to progressive ischemic injury rather than the dopaminergic neuronal loss seen in idiopathic Parkinson\u2019s disease (PD). Patients typically present with gait difficulties (often described as a 'lower body parkinsonism'), postural instability, and minimal or absent resting tremor. The classical presentation with predominantly lower limb involvement and a poor response to dopaminergic therapy (e.g., L-dopa) helps differentiate VP from idiopathic PD. Diagnosis is supported by neuroimaging studies (MRI or CT) that reveal white matter hyperintensities, lacunar infarcts, or other signs of small vessel ischemic disease. Differential diagnoses include idiopathic PD (usually tremor-dominant with good L-dopa response), normal pressure hydrocephalus, and progressive supranuclear palsy (PSP). Careful history, risk factor evaluation, and imaging help differentiate these conditions. The mainstay of treatment is aggressive control of vascular risk factors \u2013 especially hypertension \u2013 to prevent further ischemic damage. First-line management involves lifestyle modifications, strict blood pressure and diabetes control, and lipid management. Pharmacologic dopaminergic therapies (like L-dopa) are generally of limited benefit. In pregnancy and lactation, antihypertensive agents, such as labetalol or methyldopa (which are considered relatively safe in pregnancy), may be used while carefully balancing maternal and fetal risks. Regular monitoring and interdisciplinary management remain key. Option A (control hypertension) is correct. It emphasizes addressing the vascular pathology by managing modifiable risk factors. Other options (not fully presented) that might have focused on initiating dopaminergic therapy or neglecting risk factor control would be inappropriate, since VP is best managed by preventing further cerebrovascular injury. 1. VP often presents with predominant lower limb involvement and gait apraxia. 2. Levodopa response in VP is typically poor, contrasting with idiopathic PD. 3. Aggressive management of hypertension and other vascular risk factors is crucial to halt progression. Recent studies and practice guidelines continue to underscore the importance of vascular risk factor modification in the management of VP. Neuroimaging advancements have improved the differentiation of VP from other parkinsonian syndromes, reinforcing the need for individualized treatment strategies focused on vascular stabilization.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "PD for 7 yrs, Severe disabling dyskinesia on medical therapy, has mild cognitive impairment",
    "option_a": "(DBS to GPi) is the correct answer because it specifically targets dyskinesia management while preserving cognitive function. Option B (DBS to STN) is less desirable in patients with cognitive impairment since STN DBS may exacerbate such deficits. Option C (DBS to VIM) is targeted mainly for tremor control and not for dyskinesia. Option D (other nuclei) is not supported by current evidence for the management of PD dyskinesias.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Deep brain stimulation (DBS) is an established treatment for advanced Parkinson\u2019s disease (PD), especially when motor complications like severe dyskinesias develop following long\u2010term dopaminergic therapy. The typical DBS targets include the globus pallidus internus (GPi) and the subthalamic nucleus (STN). In PD, abnormal basal ganglia circuitry contributes to motor symptoms and dyskinesias. DBS modulates neural circuits: stimulation of the GPi directly mitigates dyskinesia by normalizing the inhibitory output, while STN stimulation often reduces overall medication requirements but may risk worsening cognitive functions. For a patient with a 7\u2010year history of PD, severe, disabling dyskinesia, and mild cognitive impairment, the choice of DBS target is informed by the desire to improve motor symptoms while minimizing further cognitive risks. GPi DBS is preferred over STN DBS in those with existing cognitive deficits because it is associated with a better neurocognitive safety profile. Candidates for DBS undergo thorough preoperative evaluations including motor assessments, neuropsychological testing, and detailed brain imaging. In patients with dyskinesias unmanageable by medication adjustments, these evaluations help determine the most suitable target for stimulation. First-line management of motor complications in PD involves medication adjustments. When dyskinesia becomes disabling and refractory to medical management, DBS is considered. For patients with mild cognitive impairment, GPi DBS is the first-line surgical option due to its effectiveness in controlling dyskinesia and its relatively neutral impact on cognitive function. In pregnant patients, DBS is rarely performed due to surgical and anesthesia risks; if urgent intervention is required, a multidisciplinary team should assess risks versus benefits. For lactating mothers, timing of surgery is individualized, considering both maternal health and infant exposure. Option A (DBS to GPi) is the correct answer because it specifically targets dyskinesia management while preserving cognitive function. Option B (DBS to STN) is less desirable in patients with cognitive impairment since STN DBS may exacerbate such deficits. Option C (DBS to VIM) is targeted mainly for tremor control and not for dyskinesia. Option D (other nuclei) is not supported by current evidence for the management of PD dyskinesias. 1. GPi DBS is preferred in PD patients with significant dyskinesias and mild cognitive impairment. 2. Thorough preoperative cognitive evaluation is essential in selecting the appropriate DBS target. 3. STN DBS, while effective for motor fluctuations generally, may worsen preexisting cognitive issues. Current research, including randomized controlled trials and meta-analyses, supports GPi DBS for managing dyskinetic symptoms in PD patients with cognitive concerns. Updated guidelines stress individualized treatment planning with a risk\u2013benefit discussion, particularly regarding cognitive outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario suggestive of wilson, parkinson, dystonia tx",
    "option_a": "(Penicillamine) is correct because it is the established first",
    "option_b": "",
    "option_c": ", which was the marked answer, is incorrect as it does not represent the optimal initial therapy according to established clinical guidelines.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Wilson disease is a genetic disorder of copper metabolism characterized by abnormal copper accumulation in the liver and brain. Neurological manifestations often include parkinsonism, dystonia, and tremor, among others. The treatment objective in Wilson disease is to reduce and prevent copper accumulation. Mutations in the ATP7B gene impair copper excretion by the liver, leading to copper build-up in tissues. Accumulated copper in the basal ganglia is responsible for movement disorders such as dystonia and parkinsonism. Early and effective chelation therapy can prevent irreversible neurological damage. Patients with Wilson disease may present with a combination of hepatic dysfunction and neuropsychiatric symptoms, including dystonia and parkinsonism. The presence of Kayser\u2013Fleischer rings on ophthalmologic examination is a key diagnostic clue. Prompt copper chelation can result in significant clinical improvement. The diagnostic workup for Wilson disease includes serum ceruloplasmin, 24-hour urinary copper excretion, liver function tests, and slit-lamp examination for Kayser\u2013Fleischer rings. Differential diagnoses include other causes of movement disorders and metabolic conditions; however, the age of onset and systemic findings usually aid in establishing the diagnosis. The first-line treatment for Wilson disease is chelation therapy. Penicillamine is traditionally used as the initial chelator to promote urinary excretion of copper. Alternative agents include trientine and zinc, with the latter acting by inhibiting copper absorption in the gut. In pregnancy, chelation therapy must be carefully balanced: while penicillamine can be used if necessary, lower doses and close monitoring are advised due to potential teratogenicity, and zinc is sometimes preferred for its safer profile. During lactation, the potential drug transfer to the infant should be considered, with decisions tailored to individual risk\u2013benefit assessments. Option A (Penicillamine) is correct because it is the established first-line copper chelator in Wilson disease, particularly effective in improving neurological symptoms. Although zinc and trientine are valid alternatives, they were not available among the options provided. Option C, which was the marked answer, is incorrect as it does not represent the optimal initial therapy according to established clinical guidelines. 1. Kayser\u2013Fleischer rings are a hallmark of Wilson disease and should prompt further copper studies. 2. Early initiation of chelation therapy with penicillamine is crucial in preventing irreversible neurological damage. 3. In managing Wilson disease during pregnancy, therapy must be carefully adjusted to balance maternal benefits and fetal risks. Recent guidelines and studies continue to support the use of penicillamine as first-line therapy for neurological manifestations of Wilson disease, while also emphasizing the importance of individualized treatment plans, especially during pregnancy and lactation. Emerging research is further refining the dosing and monitoring strategies to optimize outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario patient had parkinsonism restricted to LL with slowing, no tremor responding to L-dopa what is the dx",
    "option_a": "(Vascular Parkinsonism) is correct in this scenario, given the lower limb predominant parkinsonism, absence of tremor, and some response to levodopa. Option B (PSP) is unlikely due to the lack of hallmark features such as vertical gaze palsy and early falls. Option C (a non",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Vascular parkinsonism is a form of parkinsonism secondary to cerebrovascular disease. Unlike idiopathic Parkinson\u2019s disease, which primarily involves the degeneration of dopaminergic neurons in the substantia nigra, vascular parkinsonism results from ischemic damage affecting subcortical motor pathways. Cerebrovascular insults, such as lacunar infarcts and chronic small vessel ischemic changes, particularly in regions like the basal ganglia and subcortical areas, disrupt normal motor circuitry. This disruption leads to motor symptoms, most notably affecting the lower limbs. Although levodopa is the standard therapy in idiopathic PD, its efficacy in VP is usually limited; however, some patients may exhibit a partial response. Patients with vascular parkinsonism often present with gait disturbances, especially as lower body parkinsonism with predominant leg involvement, and generally lack the classic rest tremor seen in idiopathic PD. The relative sparing of the upper body and the specific gait pattern are useful clinical clues. Even though the levodopa response is typically poor, the presence of any dopaminergic responsiveness supports the involvement of dopaminergic pathways affected by vascular insults. Diagnosis is supported by brain imaging (MRI/CT) demonstrating white matter changes and infarcts consistent with small vessel disease. The differential diagnosis includes idiopathic Parkinson\u2019s disease (which typically has a robust tremor component and better response to levodopa) and progressive supranuclear palsy (PSP), which has early postural instability and gaze abnormalities. A detailed clinical history, neurologic examination, and imaging studies are essential to distinguish these disorders. The cornerstone of management in vascular parkinsonism is aggressive control of vascular risk factors, such as hypertension, diabetes, and dyslipidemia, to prevent further ischemic damage. While dopaminergic therapy (levodopa) may be tried, its benefit is generally modest. In pregnant and lactating patients, safe management of hypertension (using agents like labetalol in pregnancy) and close monitoring are imperative. Multidisciplinary care is recommended to address both neurological and cardiovascular aspects of the disease. Option A (Vascular Parkinsonism) is correct in this scenario, given the lower limb predominant parkinsonism, absence of tremor, and some response to levodopa. Option B (PSP) is unlikely due to the lack of hallmark features such as vertical gaze palsy and early falls. Option C (a non-existent syndrome) is clearly incorrect. This combination of clinical features best fits the profile of vascular parkinsonism. 1. Vascular parkinsonism typically presents with lower limb involvement and gait instability, with minimal tremor. 2. A history of vascular risk factors (especially hypertension) should raise suspicion for VP. 3. Even a partial response to levodopa may occur, but the primary treatment is risk factor modification. Current research emphasizes the importance of neuroimaging in differentiating vascular parkinsonism from idiopathic PD and other parkinsonian syndromes. Updates in clinical guidelines continue to advocate for comprehensive vascular risk management as the main therapeutic strategy, with dopaminergic therapies playing a limited adjunctive role.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "20 yo with ataxia, spasticity, sensorimotor neuropathy hypometric saccade, brain MRI showed mild cerebellar atrophy, normal immunoglobulin high alfa fetoprotein, echo normal what is the dx",
    "option_a": "(Friedreich ataxia) is incorrect because it typically shows cardiomyopathy, diabetes, and spinal cord rather than cerebellar atrophy, with normal AFP levels. Options C (OPA1) and D (OPA2) are incorrect because they are associated with optic neuropathies and do not present with the systemic neurological features (such as elevated AFP, spasticity, and sensorimotor neuropathy) seen in ataxia telangiectasia. Option B is correct as it best fits the clinical, radiological, and laboratory findings.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Ataxia telangiectasia (A\u2010T) is a rare, autosomal recessive neurodegenerative disorder characterized by progressive cerebellar ataxia, oculomotor abnormalities (such as hypometric saccades or oculomotor apraxia), and a predisposition to malignancies. Although telangiectasias are a classic feature, they may appear later in the disease course. A hallmark laboratory finding is elevated alpha-fetoprotein (AFP), while immunoglobulin abnormalities (especially IgA deficiency) are common but may occasionally be normal early on. The disease is caused by mutations in the ATM (Ataxia Telangiectasia Mutated) gene, which plays a key role in DNA repair and cellular response to double\u2010strand breaks. The defective ATM protein leads to genomic instability, improper cell cycle control, and neuronal degeneration. This accumulation of DNA damage in neurons, particularly in the cerebellum, underlies the ataxia and oculomotor abnormalities seen in patients. Typically, patients present with progressive ataxia, dyscoordination, abnormal eye movements, and sensorimotor neuropathy. Spasticity can also be observed. Although telangiectasias (small dilated blood vessels) are part of the syndrome, their absence does not rule out the diagnosis, especially in early or atypical presentations. The presence of an elevated AFP is a valuable diagnostic clue that helps differentiate A-T from disorders like Friedreich ataxia. The workup involves a detailed neurological exam, MRI imaging (which may show cerebellar atrophy), and specific laboratory studies including AFP levels. Differential diagnoses include Friedreich ataxia (which usually shows cardiomyopathy, diabetes, and spinal cord atrophy rather than cerebellar atrophy) and other hereditary ataxias. Genetic testing for ATM gene mutations can provide definitive confirmation. Although immunoglobulin deficiencies are common, normal levels do not exclude the diagnosis. Management remains primarily supportive. First-line treatment includes physical and occupational therapy to maintain mobility and coordination. Regular screening for malignancies and immunodeficiency is essential. Vaccinations should be administered per guidelines with care in immunocompromised states. In pregnancy and lactation, careful multidisciplinary planning and genetic counseling are important due to the hereditary nature and potential complications. There is ongoing research into targeted therapies, but no disease-modifying treatment is currently available. Option A (Friedreich ataxia) is incorrect because it typically shows cardiomyopathy, diabetes, and spinal cord rather than cerebellar atrophy, with normal AFP levels. Options C (OPA1) and D (OPA2) are incorrect because they are associated with optic neuropathies and do not present with the systemic neurological features (such as elevated AFP, spasticity, and sensorimotor neuropathy) seen in ataxia telangiectasia. Option B is correct as it best fits the clinical, radiological, and laboratory findings. 1) An elevated AFP in a young patient with ataxia should prompt consideration of ataxia telangiectasia even before telangiectasias develop. 2) Oculomotor abnormalities such as hypometric saccades are a key early neurological sign. 3) Genetic counseling is essential for affected families. Recent guidelines emphasize early diagnosis through genetic testing and vigilant surveillance for associated malignancies and immunodeficiency. While research into ATM-targeted therapies is ongoing, current management is supportive and multidisciplinary.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_29.png"
  },
  {
    "question": "Elderly patient presented with abnormal limb movement. He described that his left upper limb seem to move involuntarily. He reported some memory issues. On examination, he noticed to have involuntary left upper limb movement and visuospatial dissociation.\nWhich of the following is the most likely diagnosis?",
    "option_a": "Multiple system atrophy",
    "option_b": "Corticobasal degeneration",
    "option_c": "Progressive supranuclear palsy",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Corticobasal degeneration (CBD) is a neurodegenerative tauopathy that typically presents with asymmetric motor symptoms along with cortical dysfunction. It is characterized by features such as apraxia, dystonia, and cognitive impairment that may include visuospatial deficits and memory issues. CBD involves the abnormal accumulation of tau protein in neurons and glial cells within the cortex and basal ganglia. This tauopathy leads to progressive neuronal loss and dysfunction in areas that control movement and higher cognitive processing, which explains the combination of motor and cognitive symptoms. Patients with CBD often present with unilateral or highly asymmetric motor abnormalities, including involuntary movements and limb apraxia. The presence of visuospatial dissociation and memory issues correlates with the cortical involvement. These features help differentiate CBD from other parkinsonian syndromes which tend to be more symmetric or have distinct features such as vertical gaze palsy (seen in PSP). Clinical diagnosis is based on history and physical examination. Neuroimaging such as MRI may show asymmetric cortical atrophy. Differential diagnoses include Multiple System Atrophy (which is associated with autonomic dysfunction) and Progressive Supranuclear Palsy (PSP), where the latter has characteristic vertical gaze palsy. Detailed cognitive testing and sometimes PET imaging may be used to support the diagnosis. There is no disease-modifying therapy available for CBD. First-line management focuses on symptomatic treatment including physical, occupational, and speech therapy. Medications such as levodopa are often trialed, although the response is typically poor. Second-line treatments may include the use of anticholinergics or other medications to address dystonia and myoclonus. In elderly patients, careful use of these agents is essential due to side effects. During pregnancy or lactation (when applicable in familial cases or research contexts), medication choices should be carefully weighed to avoid teratogenic effects, and a multidisciplinary approach with neurology, obstetrics, and pharmacy consultations is recommended. Option A (Multiple System Atrophy) is less likely as MSA typically features early and prominent autonomic dysfunction and more symmetric parkinsonism. Option C (Progressive Supranuclear Palsy) is characterized by vertical gaze palsy and more symmetric features. Option B (Corticobasal Degeneration) is correct because it best explains the asymmetric involuntary limb movements coupled with cortical cognitive deficits such as visuospatial dissociation. 1) Asymmetry in motor symptoms is a key distinguishing feature of CBD. 2) Visuospatial deficits and apraxia are common cortical signs that help differentiate CBD from other parkinsonian syndromes. 3) The response to dopaminergic therapy in CBD is often limited. Recent studies focusing on tau-targeted therapies offer promise but are still experimental in CBD. Current standard management remains multidisciplinary supportive care with an emphasis on rehabilitation and symptomatic treatment.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient known case of DM, presented with axial and appendicular ataxia. He has conduction block. What is the likely gene mutation? (Friedreich ataxia)",
    "option_a": "CIG",
    "option_b": "CAG",
    "option_c": "GAA",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "Friedreich ataxia is an autosomal recessive inherited neurodegenerative disorder that primarily affects the spinal cord, peripheral nerves, and cerebellum. It classically presents with both axial and appendicular ataxia, and is commonly associated with additional systemic manifestations including diabetes mellitus and hypertrophic cardiomyopathy. The disorder is caused by an expanded GAA trinucleotide repeat in the first intron of the FXN gene, which leads to reduced expression of frataxin, a mitochondrial protein vital for iron homeostasis. This deficiency results in mitochondrial iron accumulation, increased oxidative stress, and subsequent neuronal degeneration. The patient\u2019s presentation of both axial and appendicular ataxia in the context of diabetes mellitus supports a diagnosis of Friedreich ataxia. Conduction block on nerve conduction studies reflects peripheral neuropathy, a common electrophysiological finding in these patients. Diagnosis is established by clinical findings supported by genetic testing to detect the GAA repeat expansion in the FXN gene. Differential diagnoses include other inherited ataxias such as spinocerebellar ataxias (often associated with a CAG triplet repeat expansion) and ataxia telangiectasia (which would have additional immunological abnormalities and elevated AFP). Cardiac evaluation with echocardiography is essential given the risk of cardiomyopathy. Management of Friedreich ataxia is predominantly supportive. First-line approaches include physical and occupational therapy to maintain mobility and manage ataxia. Cardiac management follows standard heart failure guidelines (e.g., with ACE inhibitors or beta-blockers) and careful monitoring is required. Diabetes management should conform to current endocrinological guidelines. In the context of pregnancy and lactation, multidisciplinary coordination is necessary to adjust therapies, ensure glycemic control, and appropriately monitor cardiac status. Option A (CIG) is incorrect and not associated with Friedreich ataxia. Option B (CAG) is seen in other trinucleotide repeat disorders such as Huntington\u2019s disease and some spinocerebellar ataxias. Option C (GAA) is correct as it represents the trinucleotide repeat expansion seen in Friedreich ataxia. 1) Friedreich ataxia is strongly associated with diabetes mellitus and hypertrophic cardiomyopathy. 2) Genetic testing for the GAA expansion is diagnostic. 3) Early recognition and supportive care can help manage systemic complications. Latest research continues to explore antioxidant therapies and mitochondrial-targeted treatments, but no definitive disease-modifying therapy currently exists. Ongoing clinical trials aim to better address the metabolic derangements seen in Friedreich ataxia.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with history of abnormal movements, falls, interfere with his daily routine with behavioral and mood changes, What tri-repeat would find?",
    "option_a": "CAG",
    "option_b": "CTG",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "This clinical scenario is suggestive of a neurodegenerative disorder characterized by abnormal movements, falls, and behavioral as well as mood changes. Huntington\u2019s disease, an autosomal dominant disorder, typically manifests with chorea, psychiatric disturbances, and cognitive decline. Huntington\u2019s disease is caused by a CAG trinucleotide repeat expansion in the HTT gene, leading to an abnormal huntingtin protein. This mutant protein causes neuronal dysfunction and death, particularly in the basal ganglia and cerebral cortex, resulting in the characteristic movement disorders and psychiatric symptoms. Patients commonly present with involuntary movements (chorea), frequent falls, and significant alterations in mood and behavior, which interfere with daily function. The combination of motor symptoms with cognitive and psychiatric abnormalities is pathognomonic for Huntington\u2019s disease. Diagnosis is largely based on clinical history and confirmed by genetic testing demonstrating an expanded CAG repeat in the HTT gene. Differential diagnoses include other conditions causing chorea such as Wilson\u2019s disease (with hepatic dysfunction and abnormal copper metabolism) and neuroacanthocytosis, but these are distinguished by different genetic and biochemical markers. There is no cure for Huntington\u2019s disease; management is symptomatic and multidisciplinary. First-line treatment focuses on managing chorea and psychiatric symptoms. Tetrabenazine and deutetrabenazine are used for chorea, while antipsychotics or antidepressants may be utilized for mood and behavioral issues. Non-pharmacological interventions, including physical and occupational therapy, are integral. In pregnancy and lactation, treatment requires careful balancing of maternal benefit and fetal risk, with a multidisciplinary team evaluating the risks of medications like tetrabenazine. Option A (CAG) is correct as it identifies the trinucleotide repeat expansion found in Huntington\u2019s disease. Option B (CTG) is associated with other conditions such as myotonic dystrophy and is incorrect in this context. 1) The number of CAG repeats in Huntington\u2019s disease correlates with disease onset and severity. 2) A positive family history is common due to its autosomal dominant inheritance. 3) Psychiatric symptoms often appear early and can be as disabling as the motor manifestations. Current research is focusing on gene-silencing techniques and other molecular therapies to target mutant huntingtin protein. While these approaches are promising, current treatment remains supportive and aimed at improving quality of life.",
    "exam_year": "2023",
    "exam_type": "Part I"
  },
  {
    "question": "Young lady presented to the outpatient clinic with history of abnormal movement in form of sudden abduction at the shoulder and tonic posturing of her hand noticed with writing. She has a family history of father and brother with similar condition. Which of the following is associated with this condition? (Myoclonic dystonia)",
    "option_a": "Diurnal variation",
    "option_b": "Improve with Ethanol",
    "option_c": "Early progression to dementia",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Myoclonic dystonia is a movement disorder where patients display a combination of myoclonic jerks (sudden brief muscle contractions) and dystonic posturing. It is typically inherited in an autosomal dominant pattern and often runs in families. The disorder is frequently linked to mutations in the SGCE gene (epsilon\u2010sarcoglycan), which disrupts the function of basal ganglia circuits. This disruption leads to abnormal sensorimotor integration and results in the characteristic myoclonic and dystonic movements. Recent genetic studies have further refined our understanding of the condition\u2019s heterogeneity. Patients, often young adults, present with symptoms such as involuntary jerks and abnormal postures. A classic clinical pearl is the improvement in symptoms with alcohol intake\u2014a feature that helps distinguish myoclonic dystonia from other movement disorders. A positive family history, as seen in this case, supports the inherited nature of the disorder. Diagnosis is primarily clinical, based on the pattern of movements and family history. Differential diagnoses include other forms of dystonia (e.g., dopa-responsive dystonia with its diurnal fluctuation), essential tremor, and other myoclonic syndromes. Genetic testing for SGCE mutations can support the diagnosis. Management is generally symptomatic. First-line treatment options include benzodiazepines, anticholinergics, and sometimes the use of medications like levetiracetam. Deep brain stimulation (DBS) has shown promise in refractory cases. In terms of pregnancy and lactation, many of the standard medications require review for teratogenic risks and neonatal exposure; non-pharmacologic therapies and careful dose adjustments are recommended. Although ethanol improves symptoms, its use is neither a therapeutic recommendation nor safe in pregnancy or lactation. Option A (Diurnal variation) is more characteristic of conditions like dopa-responsive dystonia, not myoclonic dystonia. Option B (Improvement with Ethanol) is the correct association with myoclonic dystonia. Option C (Early progression to dementia) is not typical for this condition and is more suggestive of neurodegenerative disorders such as Huntington disease. 1) Improvement with alcohol is a key distinguishing feature of myoclonic dystonia. 2) A positive family history strongly supports the diagnosis. 3) Genetic testing (for SGCE mutations) can confirm the diagnosis in uncertain cases. Recent research has emphasized the role of deep brain stimulation (DBS) for refractory cases of myoclonic dystonia. Additionally, genetic studies continue to elucidate genotype-phenotype correlations, potentially paving the way for more targeted therapies in the future.",
    "exam_year": "2023",
    "exam_type": "Part I"
  }
]